Treatment

favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
This study looks at new drug combinations, including KEYTRUDA, for people with advanced lung cancer. Researchers want to see how well these combinations shrink cancer (response rate) and whether they are safe.
For: Stage IV non-small cell lung cancer
Italy · Spain · Poland